CRISPR Therapeutics develops gene editing medicines, including CASGEVY, an approved therapy for sickle cell disease and beta thalassemia. CRSP reports earnings on Mon, Nov 9, 2026. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for CRSP are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRSP is in one of them and how their past CRSP trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About CRISPR Therapeutics AG
CRISPR Therapeutics is a biopharmaceutical company based in Zug, Switzerland, that develops medicines using CRISPR gene editing technology. Its approved therapy, CASGEVY, is co-developed and co-commercialized with Vertex and treats eligible patients with sickle cell disease or beta thalassemia. The company's pipeline also includes gene editing treatments for liver diseases, siRNA medicines for cardiovascular and clotting conditions, cell therapies for autoimmune diseases and cancer, and a cell-based treatment for type 1 diabetes. Its medicines target patients with serious diseases, and partners include Vertex and Eli Lilly.
